BofA Securities initiated coverage on Penumbra with a new price target
$PEN
Medical/Dental Instruments
Health Care
BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2025 | $370.00 | Neutral → Overweight | Analyst |
| 12/11/2025 | $350.00 | Neutral → Buy | Citigroup |
| 11/18/2025 | $15.00 | Underweight | Wells Fargo |
| 10/8/2025 | $326.00 | Hold → Buy | Needham |
| 9/2/2025 | $300.00 | Outperform | Evercore ISI |
| 3/14/2025 | $320.00 | Buy | BofA Securities |
| 1/21/2025 | $305.00 | Buy | UBS |
| 12/17/2024 | $275.00 | Outperform | Oppenheimer |
425 - Penumbra Inc (0001321732) (Subject)
425 - Penumbra Inc (0001321732) (Subject)
8-K - Penumbra Inc (0001321732) (Filer)
Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc., (NYSE:PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i
ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth quarter and full year 2025. Unaudited and Preliminary Financial Highlights: Fourth quarter 2025 revenue of $383.0 million to $384.8 million, which represents growth of approximately 21.4% to 22.0% compared to the fourth quarter of 2024. Excluding the impact of the China region, revenue growth was approximately 23.2% to 23.8% for the fourth quarter 2025.Revenue of $1,401.3 million
ALAMEDA, Calif., Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Event: 44th Annual J.P. Morgan Healthcare Conference Date: Monday, January 12, 2026 Time: 6:45pm ET/3:45pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks follow
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
Analyst upgraded Penumbra from Neutral to Overweight and set a new price target of $370.00
Citigroup upgraded Penumbra from Neutral to Buy and set a new price target of $350.00
Wells Fargo initiated coverage of Penumbra with a rating of Underweight and set a new price target of $15.00
Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE:PEN), The PERT Consortium® and Society for Vascular Medicine (SVM), which have come together to form the Get Out the Clot campaign, today announced findings from a new survey assessing the current state of venous thromboembolism (VTE) care, also known as blood clots in the body. Get Out the Clot is a collaborative educational initiative to help identify gaps in patient
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma
Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc., (NYSE:PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i
ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025. Revenue of $354.7 million in the third quarter of 2025, an increase of 17.8% or 16.9% in constant currency1, compared to the third quarter of 2024.Total U.S. revenue of $275.0 million in the third quarter of 2025, an increase of 21.5% compared to the third quarter of 2024.U.S. Thrombectomy revenue of $192.0 million in the third quarter of 2025, an increase of 18.5% compared to the thi
ALAMEDA, Calif., Oct. 8, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference. Management and members of the STORM-PE steering committee will discuss the Company's STORM-PE clinical trial followed by a question-and-answer session. A live webcast of the event can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion o
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G - Penumbra Inc (0001321732) (Subject)